Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02957695
Other study ID # EKNZ 2015-105
Secondary ID
Status Completed
Phase N/A
First received March 13, 2016
Last updated February 8, 2017
Start date April 2015
Est. completion date February 2017

Study information

Verified date February 2017
Source Rehab Basel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this randomized double-blind controlled study we would like to test the benefit of neurofeedback for the recovery of patients with frontal brain injury during an early stage of neurorehabilitation.


Description:

Aim of the study: Patients with a frontal brain lesion often suffer from deficits in brain functions like attention, concentration, planning, impulse control and emotional stability. In this study the investigators would like to test, whether neurofeedback as a non-medication option can help to improve these cognitive functions. Neurofeedback is a method for optimization and stabilization of the brain activity. The brain continuously gets computer-based information about its state. This information is used by the brain for self-regulation. Because neurofeedback is a process based on learning, the positive effects can be integrated into the daily life and seem to persist also after the training stopped. From the literature, several studies have shown promising results of neurofeedback therapy in patients with brain injuries, but no study so far fulfills the scientific criteria which proves a benefit. Methods: The selection of potential study participants is made by the senior or chief physician. Totally, we include 20 patients with a newly acquired frontal brain lesion. 10 patients receive normal neurofeedback training and 10 patients receive a placebo-neurofeedback in a randomized, double blinded manner. In total, 20 neurofeedback sessions are conducted. At the beginning, after 10 sessions and at the end of the intervention time, a neuropsychological assessment is performed to test the main cognitive functions of the frontal brain. Data analysis: The performance in the neuropsychological testing is the primary outcome. We expect that all participants will gain performance during the course of the study due to natural brain recovery, so that we will focus on the difference of the improvements between the two groups (neurofeedback and placebo-group).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- Middle to severe frontal or frontotemporal brain injury due to accident, bleeding or ischemia, assessed by the Initial Glascow-Coma-Scale from 3 to 12.

- Time between the injury and inclusion into the study should be 1-6 months

- The participants must be able to perform simple neuropsychologic tests including sufficient vigilance and motor function for pressing a button.

- There is no age limitation. The patients who are hospitalized in the REHAB for a initial rehabilitation have a minimum age of 18 years.

- signed consent form

Exclusion criteria:

- therapy-resistant symptomatic epilepsy

- severe cognitive deficits, which do not allow understanding of the required neuropsychological tests, e.g. sensory aphasia.

- preexisting dementia

- progressive cerebral diseases e.g. multiple sclerosis, brain tumor

- schizophrenia

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Placebo-Neurofeedback
The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
Active-Neurofeedback
The neurofeedback-method used in our study is called "infra-low frequency neurofeedback Training", developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH.

Locations

Country Name City State
Switzerland Rehab Basel Basel

Sponsors (3)

Lead Sponsor Collaborator
PD Dr. med. Margret Hund-Georgiadis Rehab Basel, Swiss Tropical & Public Health Institute

Country where clinical trial is conducted

Switzerland, 

References & Publications (6)

Benke T, Karner E, Delazer M. FAB-D: German version of the Frontal Assessment Battery. J Neurol. 2013 Aug;260(8):2066-72. doi: 10.1007/s00415-013-6929-8. — View Citation

Gevensleben H, Holl B, Albrecht B, Vogel C, Schlamp D, Kratz O, Studer P, Rothenberger A, Moll GH, Heinrich H. Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. J Child Psychol Psychiatry. 2009 Jul;50(7):780-9. doi: 10.1111/j.1469-7610.2008.02033.x. — View Citation

Lévesque J, Beauregard M, Mensour B. Effect of neurofeedback training on the neural substrates of selective attention in children with attention-deficit/hyperactivity disorder: a functional magnetic resonance imaging study. Neurosci Lett. 2006 Feb 20;394(3):216-21. — View Citation

May G, Benson R, Balon R, Boutros N. Neurofeedback and traumatic brain injury: a literature review. Ann Clin Psychiatry. 2013 Nov;25(4):289-96. Review. — View Citation

Steiner NJ, Sheldrick RC, Gotthelf D, Perrin EC. Computer-based attention training in the schools for children with attention deficit/hyperactivity disorder: a preliminary trial. Clin Pediatr (Phila). 2011 Jul;50(7):615-22. doi: 10.1177/0009922810397887. — View Citation

Wangler S, Gevensleben H, Albrecht B, Studer P, Rothenberger A, Moll GH, Heinrich H. Neurofeedback in children with ADHD: specific event-related potential findings of a randomized controlled trial. Clin Neurophysiol. 2011 May;122(5):942-50. doi: 10.1016/j.clinph.2010.06.036. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in frontal brain function assessed by FAB (Frontal assessment battery) scale 1. Change in the FAB scale (point score) assessed before, after 4 weeks of intervention and after 8 weeks of intervention Assessments are made before intervention, after 4 weeks of intervention and after 8 weeks of intervention
Primary Change in frontal brain function assessed by Alertness Test Change in the Alertness Test (T-values) assessed before, after 4 weeks of intervention and after 8 weeks of intervention Assessments are made before intervention, after 4 weeks of intervention and after 8 weeks of intervention
Primary Change in frontal brain function assessed by the GoNogo-Test Change in the GoNogo-Test (T-values) assessed before, after 4 weeks of intervention and after 8 weeks of intervention Assessments are made before intervention, after 4 weeks of intervention and after 8 weeks of intervention
Primary Change in frontal brain function assessed by the Emotion recognition Test Change in the Emotion recognition Test (T-values) assessed before, after 4 weeks of intervention and after 8 weeks of intervention Assessments are made before intervention, after 4 weeks of intervention and after 8 weeks of intervention
Secondary Change in behaviour assessed by the Frontal Systems Behavioral Scale (FrSBe) FrSBe is a questionnaire to assess behaviour as an important frontal brain function. This questionnaire is filled out by the responsible nurse and as a self-rating form by the patient himself. The improvement in behaviour measured by the questionnaire (T-values) assessed before, after 4 weeks and after 8 weeks of Intervention is a secondary outcome. Assessments are made before intervention, after 4 weeks of intervention and after 8 weeks of intervention
Secondary Change in quantitative eeg z-scores of coherence and relative power Difference in z-scores of quantitative eeg measured before and after 8 weeks of intervention Assessment is made before and after 8 weeks of intervention
See also
  Status Clinical Trial Phase
Recruiting NCT03458676 - Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies N/A
Completed NCT01428778 - Berlin Beat of Running Study N/A
Completed NCT03603106 - Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions Phase 1/Phase 2
Recruiting NCT05267587 - Preop fSRS for Resectable Brain Metastases Phase 2
Recruiting NCT03410810 - Childhood Outcomes of Preterm Brain Abnormalities
Recruiting NCT04742231 - Handheld Dynamometer During Awake Craniotomy Pilot N/A
Completed NCT02549313 - Effect of the Position of the Patient's Head N/A
Recruiting NCT03586258 - Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage 2 N/A
Completed NCT04585503 - Feasibility Study of Cortical Recording Depolarizations in Brain-injured Patients, and Their Use as Biomarkers of New Lesions. N/A
Completed NCT02656407 - Intraoperative Functional Ultrasound N/A
Recruiting NCT03593330 - Neurosurgical Transitional Care Programme N/A